The US Food and Drug Administration is working diligently to provide the public with information to keep consumers well and safe. From hand sanitizers to testing to food safety, this slideshow presents the latest developments.
Heidi Anne Duerr, MPH
How will the coronavirus pandemic impact psychiatry as a field? Are there any neuropsychiatric symptoms associated with the COVID-19 virus? Those questions answered in this video.
What do we tell patients regarding the pandemic both in terms of office policies and preparations for self-isolation and quarantine as well as dealing with uncertainty?
Psychiatric Times has collected information to answer your most pressing questions, including how to prepare your office and staff, resources for patients, and information you need to implement telepsychiatry.
As we navigate uncharted waters on the pandemic front, John J. Miller, MD, shares his thought about this important topic and what he is doing differently both professionally and personally.
Psychiatric Times wants to know how the pandemic is impacting your practice and your lives.
What can psychiatrists in the US do to better prepare themselves and their patients for potential natural disasters? Dr Armen Goenjian, research psychiatrist at the David Geffen School of Medicine at University of California, Los Angeles, answers that question and more in this Psychiatric Times exclusive.
After receiving complaints, the FDA’s Office of Prescription Drug Promotion rebukes the pharmaceutical company for misleading advertising.
The FDA accepts a New Drug Application for novel antidepressant.
Drug companies are investing more to study psychiatric disorders, and there may be novel treatments in the near future.